Satraplatin for hormone-refractory prostate cancer

被引：4

|

作者：

Kerr, Cathel

机构：

来源：

LANCET ONCOLOGY | 2007年 / 8卷 / 04期

关键词：

D O I：

10.1016/S1470-2045(07)70096-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

收藏

页码：290 / 290

页数：1

相关论文

共 50 条

[1] Satraplatin in the treatment of hormone-refractory prostate cancer
Sternberg, CN
[J]. BJU INTERNATIONAL, 2005, 96 (07) : 990 - 994
[2] Satraplatin in the treatment of hormone-refractory prostate cancer (vol 96, pg 990, 2005)
Sternberg, CN
[J]. BJU INTERNATIONAL, 2006, 97 (01) : 211 - 211
[3] Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour TypesPharmacological Properties and Clinical Evaluation
Mark J. McKeage
[J]. Drugs, 2007, 67 : 859 - 869
[4] Hormone-Refractory prostate cancer
Rini B.I.
Small E.J.
[J]. Current Treatment Options in Oncology, 2002, 3 (5) : 437 - 446
[5] Satraplatin in hormone-refractory prostate cancer and other tumour types - Pharmacological properties and clinical evaluation
McKeage, Mark J.
[J]. DRUGS, 2007, 67 (06) : 859 - 869
[6] Satraplatin demonstrates clinical benefit in patients with advanced hormone-refractory prostate cancer: Results of the global phase III satraplatin and prednisone against refractory cancer (sparc) trial
Sartor, O.
Petrylak, D.
Witjes, F.
Berry, W.
Chatta, G.
Vaughn, D.
Sternberg, C. N.
[J]. CANCER INVESTIGATION, 2007, 25 : 19 - 20
[7] Management of hormone-refractory prostate cancer
Dogliotti, L
Mosca, A
[J]. TUMORI, 2003, : S147 - S149
[8] Chemotherapy of the hormone-refractory prostate cancer
Heine, K
Wolff, JM
[J]. AKTUELLE UROLOGIE, 2004, 35 (03) : 209 - 214
[9] Taxanes in hormone-refractory prostate cancer
Kang, MH
Figg, WD
Dahut, W
[J]. CANCER PRACTICE, 1999, 7 (05) : 270 - 272
[10] Therapy of hormone-refractory prostate cancer
Heidenreich, A
[J]. UROLOGE, 2005, 44 (12): : 1481 - 1494

← 1 2 3 4 5 →